Corbus Pharmaceuticals is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates.
Learn More
Our technology is built on robust underlying science based on the endocannabinoid system as a master regulator of inflammation and fibrosis in the body.
Learn More
Corbus Pharmaceuticals is dedicated to developing therapeutics that help to better the lives of patients with chronic inflammatory and fibrotic conditions.
Learn MoreOur pipeline is built on robust underlying science based on the endocannabinoid system as a master regulator of inflammation and fibrosis in the body.
View DetailsSystemic Sclerosis
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
|---|---|---|---|---|
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
Launch Phase not started
|
Targeting 2021 launch
Dermatomyositis
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
|---|---|---|---|---|
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
Launch Phase not started
|
Systemic Lupus Erythematosus
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
|---|---|---|---|---|
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Launch Phase not started
|
Cystic Fibrosis
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
|---|---|---|---|---|
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Launch Phase not started
|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
|---|---|---|---|---|
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Launch Phase not started
|
Scheduled to Enter Phase 1 in 2019, NIH Committed to Funding Phase 2 Study.
Goal: 1-2 new Phase 1 programs per year starting in 2020
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
|---|---|---|---|---|
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Launch Phase not started
|
A novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes.
